Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2025

Nov 13, 2025

SELL
$5.62 - $9.62 $165,228 - $282,828
-29,400 Reduced 61.76%
18,200 $162,000
Q2 2025

Aug 14, 2025

SELL
$5.28 - $7.06 $358,512 - $479,374
-67,900 Reduced 58.79%
47,600 $260,000
Q1 2025

May 14, 2025

BUY
$3.66 - $6.81 $422,730 - $786,555
115,500 New
115,500 $726,000

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $661M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.